MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317383 | Name: Cefazolin Sodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Cefazolin inhibits synthesis of bacterial cell wall. Cefazolin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, which results in the weakening of the bacterial cell wall and cell lysis.

Chemical Structure

Cefazolin Sodium
Cefazolin Sodium
CAS#27164-46-1 (sodium)

Theoretical Analysis

MedKoo Cat#: 317383

Name: Cefazolin Sodium

CAS#: 27164-46-1 (sodium)

Chemical Formula: C14H13N8NaO4S3

Exact Mass: 0.0000

Molecular Weight: 476.49

Elemental Analysis: C, 35.29; H, 2.75; N, 23.52; Na, 4.82; O, 13.43; S, 20.19

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
5g USD 450.00 2 Weeks
10g USD 650.00 2 Weeks
25g USD 1,150.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
25953-19-9 (free base) 27164-46-1 (sodium)
Synonym
Cefazolin Sodium; Cefazolin; Sodium cephazolin; Cefazolin sodium salt; Sodium cefazolin
IUPAC/Chemical Name
sodium;(6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
InChi Key
FLKYBGKDCCEQQM-WYUVZMMLSA-M
InChi Code
InChI=1S/C14H14N8O4S3.Na/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21;/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26);/q;+1/p-1/t9-,12-;/m1./s1
SMILES Code
CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)[O-].[Na+]
Appearance
White to off-white solid powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 476.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sivakumar B, Parthasarathy K, Murugan R, Jeyasudha R, Murugan S, Saranghdar RJ. Isolation and characterisation of degradation impurities in the cefazolin sodium drug substance. Sci Pharm. 2013 Jun 4;81(4):933-50. doi: 10.3797/scipharm.1304-14. eCollection 2013 Dec. PubMed PMID: 24482765; PubMed Central PMCID: PMC3867249. 2: Wei D, Zhou R, cheng S, Feng W, Li B, Wang Y, Jia D, Zhou Y, Guo H. Microarc oxidized TiO2 based ceramic coatings combined with cefazolin sodium/chitosan composited drug film on porous titanium for biomedical applications. Mater Sci Eng C Mater Biol Appl. 2013 Oct;33(7):4118-25. doi: 10.1016/j.msec.2013.05.053. Epub 2013 Jun 6. PubMed PMID: 23910322. 3: Sun H, Wang J, Wang T. Development of a novel chemiluminescence method for the determination of cefazolin sodium in injectable powder and human urine based on a luminol-Cu(III) complex reaction in alkaline medium. Luminescence. 2013 Jul-Aug;28(4):592-6. doi: 10.1002/bio.2398. Epub 2012 Jul 15. PubMed PMID: 22807137. 4: Akkaya S, Nazalı M, Kılıç A, Bir F. Cefazolin-sodium has no adverse effect on fracture healing in an experimental rabbit model. Eklem Hastalik Cerrahisi. 2012 Apr;23(1):44-8. PubMed PMID: 22448830. 5: Donnelly RF. Stability of cefazolin sodium in polypropylene syringes and polyvinylchloride minibags. Can J Hosp Pharm. 2011 Jul;64(4):241-5. PubMed PMID: 22479065; PubMed Central PMCID: PMC3161797. 6: Yoruk O, Ucuncu H, Sutbeyaz Y, Aktan B, Gur FO. The effects of methylprednisolone and cefazolin sodium on antioxidant status in experimentally induced maxillary sinusitis. Acta Otolaryngol. 2009 Oct;129(10):1101-5. doi: 10.1080/00016480802552584. PubMed PMID: 19031299. 7: Crucq AS, Slegers C, Deridder V, Tilquin B. Radiosensitivity study of cefazolin sodium. Talanta. 2000 Aug 16;52(5):873-7. PubMed PMID: 18968047. 8: Hu CQ, Yin LH, Liang YN. [Physical and chemical characteristics of a new cefazolin sodium hydrate crystal]. Yao Xue Xue Bao. 2008 Aug;43(8):868-72. Chinese. PubMed PMID: 18956782. 9: Akula KK, Dhir A, Kulkarni SK. Pro-convulsant effect of cefazolin sodium against pentylenetetrazol- or picrotoxin-induced convulsions in mice. Indian J Exp Biol. 2007 Aug;45(8):720-5. PubMed PMID: 17877149. 10: Tayama E, Arinaga K, Shojima T, Takagi K, Yokokura Y, Yoshikawa K, Hori H, Fukunaga S, Akashi H, Aoyagi S. Infection management in a patient with a left ventricular assist device: a case report of long-term cefazolin sodium hydrate administration. J Artif Organs. 2006;9(2):118-21. PubMed PMID: 16807815. 11: Zou L, Fan XG, Gui H. [Sensitivity of nanoparticlized cefazolin sodium to the bacteria in vitro]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Jun;30(3):318-20. Chinese. PubMed PMID: 16045023. 12: El-Desoky HS, Ghoneim EM, Ghoneim MM. Voltammetric behavior and assay of the antibiotic drug cefazolin sodium in bulk form and pharmaceutical formulation at a mercury electrode. J Pharm Biomed Anal. 2005 Oct 4;39(5):1051-6. Epub 2005 Jul 7. PubMed PMID: 16005594. 13: Pyne A, Suryanarayanan R. The effect of additives on the crystallization of cefazolin sodium during freeze-drying. Pharm Res. 2003 Feb;20(2):283-91. PubMed PMID: 12636169. 14: How TH, Loo WY, Yow KL, Lim LY, Chan EW, Ho PC, Chan SY. Stability of cefazolin sodium eye drops. J Clin Pharm Ther. 1998 Feb;23(1):41-7. PubMed PMID: 9756111. 15: Lee DK, Wong CY, Wang DP. Stability of cefazolin sodium and meperidine hydrochloride. Am J Health Syst Pharm. 1996 Jul 1;53(13):1608, 1610. PubMed PMID: 8809288. 16: Wang DP, Chang LC, Wong CY, Lee DK. Stability of cefazolin sodium-famotidine admixture. Am J Hosp Pharm. 1994 Sep 1;51(17):2205, 2209. PubMed PMID: 7985704. 17: Rivers TE, McBride HA, Trang JM. Stability of cefazolin sodium and metronidazole at 8 degrees C for use as an i.v. admixture. J Parenter Sci Technol. 1993 May-Jun;47(3):135-7. PubMed PMID: 8360806. 18: Jacob E, Cierny G 3rd, Fallon MT, McNeill JF Jr, Siderys GS. Evaluation of biodegradable cefazolin sodium microspheres for the prevention of infection in rabbits with experimental open tibial fractures stabilized with internal fixation. J Orthop Res. 1993 May;11(3):404-11. PubMed PMID: 8326446. 19: Nahata MC, Ahalt PA. Stability of cefazolin sodium in peritoneal dialysis solutions. Am J Hosp Pharm. 1991 Feb;48(2):291-2. PubMed PMID: 2003503. 20: Stiles ML, Tu YH, Allen LV Jr. Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm. 1989 Jul;46(7):1408-12. PubMed PMID: 2667354.